This invention relates to a method for modulating, inhibiting or decreasing
or preventing beta cell degeneration, loss of beta cell function, beta
cell dysfunction, and/or death of beta cells, such as necrosis or
apoptosis of beta cells in a subject comprising administering a GLP-1
agonist to said subject.
